NCT05857774

Brief Summary

Air is normally pumped in and out of the lungs by the muscles that contribute to inhalation and exhalation, called the respiratory muscles. The abdominal muscles help by forcing air out of your lungs during exhalation; whereas the diaphragm, the main muscle used for breathing, contracts to get air into the lungs during inhalation. With mechanical ventilation, respiratory muscles are able to rest and recover while the breathing machine takes over; however, this may cause respiratory muscle weakness. Patients who develop weakness of these muscles may require more assistance from the ventilator and take longer to recover their ability to breathe without assistance. The impact of this phenomenon on long-term outcomes is uncertain. The RESPIRE study is designed to characterize how respiratory muscles change during mechanical ventilation and to evaluate the impact on long term quality of life. An additional objective of this study is to examine novel measures obtained from automated functions of a ventilator, that may better predict success from weaning from mechanical ventilation.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
230

participants targeted

Target at P75+ for all trials

Timeline
2mo left

Started Apr 2023

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress95%
Apr 2023Jun 2026

First Submitted

Initial submission to the registry

March 2, 2023

Completed
2 months until next milestone

Study Start

First participant enrolled

April 27, 2023

Completed
18 days until next milestone

First Posted

Study publicly available on registry

May 15, 2023

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2026

Expected
Last Updated

May 21, 2024

Status Verified

May 1, 2024

Enrollment Period

2.7 years

First QC Date

March 2, 2023

Last Update Submit

May 18, 2024

Conditions

Outcome Measures

Primary Outcomes (2)

  • Quality of life at home

    5-level EQ-5D (EQ-5D-5L) score - The EQ-5D-5L is a validated self-reported instrument assessing quality of life at the moment questionnaire is completed. Each question is scored from 1 (no problems) to 5 (inability to perform activity) and are independently assessed.

    Day 180

  • Quality of life at home

    Montreal Cognitive Assessment (MOCA) score - MoCA is a clinician-reported measure to assess for cognitive impairments. MoCA is scored out of 30 with scores \<26 indicating cognitive impairment.

    Day 180

Secondary Outcomes (10)

  • Duration of ventilation

    Until hospital discharge (up to 6 months)

  • Muscle research council score

    Until day 14

  • Airway occlusion pressure (P0.1)

    First spontaneous breathing trial (within 5 minutes of onset)

  • Expiratory occlusion pressure (Pocc)

    First spontaneous breathing trial (within 5 minutes of onset)

  • Maximal inspiratory pressure (MIP)

    First spontaneous breathing trial within 30 minutes of onset

  • +5 more secondary outcomes

Study Arms (3)

Cases

Adult patients ≥18 years of age undergoing invasive mechanical ventilation in the ICU for any reason within 36 hours of intubation

Other: Sonographic measurementsOther: Physiological measurementsOther: Biological measurements

Control condition A

Non-invasively ventilated patients in the ICU within 36 hours of initiating non-invasive ventilation

Other: Sonographic measurementsOther: Physiological measurementsOther: Biological measurements

Control condition B

Non-ventilated patients admitted to the ICU receiving no respiratory support or oxygen therapy alone, including high flow nasal cannula

Other: Sonographic measurementsOther: Physiological measurementsOther: Biological measurements

Interventions

Diaphragm thickness, diaphragm tidal thickening fraction, abdominal muscle thickness, rectus femoris cross-sectional area, maximal diaphragm thickening fraction, abdominal muscle thickening fraction

CasesControl condition AControl condition B

Airway occlusion pressure, maximal inspiratory pressure, muscle research council score

CasesControl condition AControl condition B

Skeletal troponin-I

CasesControl condition AControl condition B

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients will be enrolled in the Medical-Surgical ICU at Toronto General Hospital.

You may qualify if:

  • Adult patients ≥18 years of age undergoing invasive mechanical ventilation in the ICU for any reason within 36 hours of intubation
  • Non-invasively ventilated patients in the ICU within 36 hours of initiating non-invasive ventilation
  • Non-ventilated patients admitted to the ICU receiving no respiratory support or oxygen therapy alone, including high flow nasal cannula

You may not qualify if:

  • Patients expected to be extubated within 24 hours of screening for eligibility
  • Patients who have already undergone a SBT at time of screening
  • Patients with a previously diagnosed neuromuscular disorder
  • Patients receiving long-term invasive mechanical ventilation (prior to current hospitalization)
  • Patients who have required previously (during current hospitalization) a period of invasive ventilation in ICU of more than 24 hours
  • Patients who have previously been enrolled in the study
  • Patients for whom post-hospital follow-up may be challenging, e.g. those who reside overseas or who have no fixed address

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Toronto General Hospital

Toronto, Ontario, M5G 2N2, Canada

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Skeletal Troponin-I

MeSH Terms

Conditions

Lung InjuryRespiratory Insufficiency

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesThoracic InjuriesWounds and InjuriesRespiration Disorders

Study Officials

  • Ewan Goligher, MD, PhD

    University Health Network, Toronto

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Rongyu (Cindy) Jin

CONTACT

Catherine Bellissimo, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 2, 2023

First Posted

May 15, 2023

Study Start

April 27, 2023

Primary Completion

December 31, 2025

Study Completion (Estimated)

June 30, 2026

Last Updated

May 21, 2024

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will not share

Locations